EP Patent

EP4674486A3 — Solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridin-2-yl)-n-benzylacetamide

Assigned to Atnx Spv LLC · Expires 2026-03-25 · 0y expired

What this patent protects

The present application provides solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridine-2-yl)-N-benzylacetamide, and methods of preparing and using the same.

USPTO Abstract

The present application provides solid forms of 2-(5-(4-(2-morpholinoethoxy)phenyl)pyridine-2-yl)-N-benzylacetamide, and methods of preparing and using the same.

Drugs covered by this patent

Patent Metadata

Patent number
EP4674486A3
Jurisdiction
EP
Classification
—
Expires
2026-03-25
Drug substance claim
No
Drug product claim
No
Assignee
Atnx Spv LLC
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.